Skip to content
2000
Volume 19, Issue 10
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

HELLP syndrome is a disorder associated with serious maternal morbidity and mortality. Distinguishing HELLP from other pregnancy-related disorders is often challenging and may result in delay of treatment. Differential diagnoses include acute fatty liver of pregnancy, thrombotic thrombocytopenic purpura, antiphospholipid syndrome, and hemolytic uremic syndrome, and are reviewed in this chapter. While there is not any current treatment for HELLP, the mainstay of treatment involves maternal stabilization and timely delivery. Various treatment strategies have been attempted to help decrease the morbidity and mortality of HELLP, including the maternal use of corticosteroids. The authors review the studies and controversies surrounding the maternal use of corticosteroids, plasma exchange, and low molecular weight heparin for the treatment of HELLP, as well as the role of the complement system in HELLP. Further large, well-designed, randomized controlled trials are needed to address the role corticosteroids may play in the treatment of women with HELLP and to help improve maternal and fetal outcomes.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201019666180712115215
2018-09-01
2025-06-17
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201019666180712115215
Loading

  • Article Type:
    Review Article
Keyword(s): complement; corticosteroids; HELLP syndrome; hypertension; preeclampsia; thrombocytopenia
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test